Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines

This is a Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single/repeated injections of Eveotox in the treatment of moderate to severe glabellar lines. The study consists of Study Part 1 (randomized double-blind controlled study) and Part 2 (open-label study). Part I is a multicenter, randomized, double-blind, single-injection, active-controlled and placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of Eveotox in the treatment of moderate to severe glabellar lines; Part 2 is an open-label study to evaluate the efficacy, safety, and immunogenicity of repeated injections of Eveotox in the treatment of moderate to severe glabellar lines.

NCT Number	NCT06937944
Lead Sponsor	JHM BioPharma (Tonghua) Co. , Ltd.
Conditions	Moderate to Severe Glabellar Lines
Enrollment	669 participants
Start Date	2025-04-30
Primary Completion	2026-02-09 (estimated)
Study Completion	2026-08 (estimated)
Updated on ClinicalTrials.gov	2026-08-05